This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and biggest market movers. Market Checkup gives a full examination of a shocking medical device takeover, a hot biotech that can't find an acquirer, a surprise announcement bringing a failed drug, and a big deal in gene sequencing.
In this video, health-care analyst David Williamson discusses Clovis Oncology's failed bid to sell itself. After hanging a for-sale sign on the door, but with no interested parties stepping forward, where does that leave Clovis? Watch and find out along with further details about why its drug pipeline has investors excited.
David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.